Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

Jain MD, Bachmeier CA, Phuoc VH, Chavez JC

Therapeutics and Clinical Risk Management 2018, 14:1007-1017

Published Date: 31 May 2018